Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma

PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions

Asthma

Interventions

BIOLOGICAL

Tezepelumab

Monoclonal antibody designed for the treatment asthma.

BIOLOGICAL

Placebo

Matched placebo.

Trial Locations (1)

RECRUITING

Firestone Institute for Respiratory Health, Hamilton

All Listed Sponsors

lead

McMaster University

OTHER